[{"id":"6151f3df-8e2e-4964-850d-c170b0c3a37a","acronym":"DART","url":"https://clinicaltrials.gov/study/NCT04392505","created_at":"2021-01-18T21:12:06.849Z","updated_at":"2025-02-25T14:59:05.750Z","phase":"Phase 2","brief_title":"Durvalumab(MEDI4736) After chemoRadioTherapy(DART) for NSCLC-a Translational and Biomarker Study","source_id_and_acronym":"NCT04392505 - DART","lead_sponsor":"Oslo University Hospital","biomarkers":" PD-L1 • TMB","pipe":" | ","alterations":" TMB-H • TMB-L","tags":["PD-L1 • TMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TMB-H • TMB-L"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 05/11/2020","start_date":" 05/11/2020","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 05/01/2033","study_completion_date":" 05/01/2033","last_update_posted":"2024-02-29"},{"id":"b9b26734-bbcd-40dd-a6fb-92b73cac9819","acronym":"CheckMate 568","url":"https://clinicaltrials.gov/study/NCT02659059","created_at":"2021-01-17T17:12:06.946Z","updated_at":"2024-07-02T16:35:51.356Z","phase":"Phase 2","brief_title":"Nivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT02659059 - CheckMate 568","lead_sponsor":"Bristol-Myers Squibb","biomarkers":" PD-L1 • TMB","pipe":" | ","alterations":" PD-L1 expression • TMB-H • PD-L1 negative • TMB-L","tags":["PD-L1 • TMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • TMB-H • PD-L1 negative • TMB-L"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • cisplatin • Yervoy (ipilimumab) • carboplatin • paclitaxel • pemetrexed"],"overall_status":"Completed","enrollment":" Enrollment 324","initiation":"Initiation: 02/15/2016","start_date":" 02/15/2016","primary_txt":" Primary completion: 06/22/2018","primary_completion_date":" 06/22/2018","study_txt":" Completion: 03/07/2022","study_completion_date":" 03/07/2022","last_update_posted":"2023-04-05"},{"id":"44f74867-a452-465f-b2dd-f20c18d06dee","acronym":"","url":"https://clinicaltrials.gov/study/NCT03546452","created_at":"2021-07-14T02:52:47.072Z","updated_at":"2024-07-02T16:37:10.220Z","phase":"","brief_title":"A Prospective Study to Evaluate the Consistency of Next-Generation Sequencing(NGS)-Panels by Using Malignant Hydrothorax Form NSCLC","source_id_and_acronym":"NCT03546452","lead_sponsor":"Shanghai Chest Hospital","biomarkers":" TMB","pipe":" | ","alterations":" TMB-H • TMB-L","tags":["TMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TMB-H • TMB-L"],"overall_status":"Unknown status","enrollment":" Enrollment 50","initiation":"Initiation: 05/18/2018","start_date":" 05/18/2018","primary_txt":" Primary completion: 09/30/2018","primary_completion_date":" 09/30/2018","study_txt":" Completion: 05/01/2019","study_completion_date":" 05/01/2019","last_update_posted":"2018-06-07"}]